United Kingdom (UK)
Recombinant monoclonal antibody to CTGF. Manufactured using AbAb’s Recombinant Platform with variable regions (i.e. specificity) from the hybridoma HL2198.
UniProt Accession Number of Target Protein: P29279
Alternative Name(s) of Target: Connective Tissue Growth factor; CCN family member 2; Cellular communication network factor 2; Connective tissue growth factor; Hypertrophic chondrocyte-specific protein 24; Insulin-like growth factor-binding protein 8; IBP-8; IGF-binding protein 8; IGFBP-8
Immunogen: The original version of this antibody was raised by immunizing mice against a peptide representing aa 81-94 of hCTGF corresponding to part of the 2nd domain (Von Willebrand Factor – Type C Repeat).
Specificity: This antibody binds aa 81-94 of hCTGF corresponding to the 2nd domain (Von Willebrand Factor – Type C Repeat). CTGF is a cysteine-rich, matrix-associated, heparin-binding protein. It corss-reacts with similar proteins form the CCN family, such as hCYR1 and hNOV. In vitro, CTGF mediates some of the effects of TGF-beta on skin fibroblasts, such as stimulation of extracellular matrix production, chemotaxis, proliferation and integrin expression. CTGF can promote endothelial cell growth, migration, adhesion and survival and is implicated in endothelial cell function and angiogenesis. CTGF has been implicated in extracellular matrix remodeling in wound healing, scleroderma and other fibrotic processes, as it is capable of up-regulating both matrix metalloproteinases (MMPs) and their inhibitors (TIMPs). Thus, CTGF has the potential to activate both the synthesis and degradation of extracellular matrix.
Application Notes: Proteolytically generated fragments of CTGF that retain functionality have been measured in biological fluids; this monoclonal antibody was designed with the intention to: a) discern between cleaved and uncleaved forms on the basis of a loss of immunoreactivity after cleavage (i.e. aa 187-197). This clone bindsaa 81-94 of hCTGF corresponding to the 2nd domain (Von Willebrand Factor – Type C Repeat). b) Develop a sandwich ELISA using two mAbs per fragment, where one mAb is the capture antibody and the other is the detector (together with our non-competitive clones Ab02551 (HL2180) and Ab02552 (HL2181) which recognize distinct regions of CTGF.
Antibody first published in: PMID: